Popular terms

Autoimmune Diseases topics
Immune Diseases
Autoimmune Disease
Autoimmune Diseases
Immune Disease
Autoimmune
Rheumatoid Arthritis
Antibodies
Proliferative
Nucleotide
Antagonist
Infectious Diseases
Inflammatory Disease
Infectious Disease
Infectious
Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune Diseases patents



      

This page is updated frequently with new Autoimmune Diseases-related patent applications.




Date/App# patent app List of recent Autoimmune Diseases-related patents
04/28/16
20160116469 
 Immunologically active polypeptide patent thumbnailnew patent Immunologically active polypeptide
Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc


04/28/16
20160115126 
 Indole carboxamide compounds patent thumbnailnew patent Indole carboxamide compounds
Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

04/21/16
20160109443 
 Detection of gluten-specific t-cells patent thumbnailDetection of gluten-specific t-cells
The present invention relates to compositions and methods for visualizing disease-specific t-cells. In particular, the present invention relates to compositions and methods for use in the diagnosis, monitoring of progression, monitoring of response to therapy, and selection of patients for therapy of autoimmune diseases characterized by selective expansion of disease-specific effector memory t-cells..

04/14/16
20160103137 
 Method for the analysis of n-glycans attached to immunoglobulin g from human blood plasma and its use patent thumbnailMethod for the analysis of n-glycans attached to immunoglobulin g from human blood plasma and its use
From the results of the analysis, glycan age index (gai) is calculated, and it is useful for: prediction of biological age of a tested individual; monitoring efficacy of methods that slow down the ageing process; monitoring progression of diseases that are developed as a result of the ageing process advancement, like: inflammatory diseases (including atherosclerosis), autoimmune diseases, tumours, diabetes, arthritis, osteoporosis, and alzheimer disease; and evaluation of overall condition/health of a body.. .

04/14/16
20160101189 
 Monomers and oligonucleotides comprising cycloaddition adduct(s) patent thumbnailMonomers and oligonucleotides comprising cycloaddition adduct(s)
In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

04/07/16
20160095895 
 Highly concentrated formulations of soluble fc receptors patent thumbnailHighly concentrated formulations of soluble fc receptors
The present invention relates to novel formulations of soluble fc receptors and especially to formulations containing high concentrations of soluble fcγriib receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved..
Suppremol Gmbh


04/07/16
20160095839 
 Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions patent thumbnailMethod of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.


03/24/16
20160083473 
 Bispecific constructs and their use in the treatment of various diseases patent thumbnailBispecific constructs and their use in the treatment of various diseases
The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.. .
Numab Ag


03/24/16
20160082017 
 Estriol therapy for multiple sclerosis and other autoimmune diseases patent thumbnailEstriol therapy for multiple sclerosis and other autoimmune diseases
The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (ms), rheumatoid arthritis (ra), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis..

03/17/16
20160075999 
 Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases patent thumbnailMethod for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases
A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell.
Gwo Xi Stem Cell Applied Technology Co., Ltd.


03/17/16
20160075790 

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company


03/17/16
20160074505 

Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases


A method and system for targeting the microbiome to promote health involves exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies and autoimmune diseases. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..

03/10/16
20160069896 

Diagnosis of autoimmune diseases using a specific antibody profile


Methods and kits for diagnosing systemic lupus erythematosus (sle) or scleroderma in a subject are provided. Particularly, the present invention relates to a specific antibody reactivity profile useful in diagnosing sle or scleroderma in a subject..
Yeda Research And Development Co., Ltd.


03/10/16
20160068809 

Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants


The invention relates to the use of 1-(β-d-ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of indoleamine 2,3-dioxygenase (ido) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.. .
Idogen Ab


03/10/16
20160068534 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/10/16
20160068524 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/10/16
20160068522 

Inhibitors of leukotriene a4 hydrolase


The present invention is directed to compounds encompassed by the formula (i), pharmaceutical compositions thereof, methods for inhibiting lta-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of lta4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders..
Celtaxsys, Inc.


03/03/16
20160060700 

Copy number variations and autoimmune diseases


This disclosure describes methods of determining the copy number of fcgr3a and/or fcgr3b in the genome of an individual, which is shown herein to be statistically significantly associated with an increased risk of the individual developing an autoimmune disease.. .
Regents Of The University Of Minnesota


03/03/16
20160060299 

Macrocyclic therapeutic agents and methods of treatment


The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Inc.


03/03/16
20160060264 

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


03/03/16
20160060237 

Ido inhibitors


There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (i)..
Bristol-myers Squibb Company


03/03/16
20160058792 

Methods and compositions of treating autoimmune diseases


Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerogenic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the il 27/ectonucleotidase cd39 axis signaling.
The Brigham And Women's Hospital, Inc.


02/25/16
20160053007 

Antibodies that bind to tl1a and methods of treating inflammatory or autoimmune disease comprising administering such antibodies


Methods and compositions for treating inflammatory or autoimmune diseases in a subject comprising blocking the interaction between dr3 and tl1a. In the methods of treating inflammatory or autoimmune disease, the inflammatory or autoimmune disease can be an autoimmune disease with a t cell component, including asthma, multiple sclerosis, rheumatoid arthritis, type 1 diabetes, graft versus host disease or inflammatory bowel disease..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


02/25/16
20160052888 

Substituted bicyclic compounds


And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

02/25/16
20160052876 

Cryopyrin inhibitors for preventing and treating inflammation


Inhibitors that are anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as heart failure and autoimmune diseases.. .
Virginia Commonwealth University


02/25/16
20160051671 

Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease


The invention relates to novel combination therapies involving blys or blys/april inhibition and anti-cd20 agents for the treatment of autoimmune diseases. One preferred method is where the blys antagonist is a fc-fusion protein which can be a taci-fc-fusion protein comprising the extracellular domain of taci or a functional fragment thereof, a baff-r-fc-fusion protein comprising the extracellular domain of baff-r or a functional fragment thereof, or a bcma-fc-fusion protein comprising the extracellular domain of bcma or a functional fragment thereof.
Zymogenetics, Inc.


02/25/16
20160051573 

Structure and use of 5' phosphate oligonucleotides


Oligonucleotides bearing free, uncapped 5′ phosphate group(s) are recognized by rig-i, leading to the induction of type i ifn, il-18 and il-1β production. Bacterial rna also induces type i ifn production.
Rheinische Friedrich-wilhelms-universität Bonn


02/18/16
20160046714 

Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity


The present invention provides methods of treating, preventing, slowing the progression of, or ameliorating the symptoms of t cell mediated immunological diseases, particularly autoimmune diseases (e.g., autoimmune diabetes (i.e. Type 1 diabetes or insulin-dependent diabetes mellitus (iddm)) and multiple sclerosis) through the use of anti-human cd3 antibodies.
Macrogenics, Inc.


02/18/16
20160046661 

Ras inhibitors and uses thereof


Described herein are compounds of formulae (i)-(ii), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject..
Dana-farber Cancer Institute, Inc.


02/18/16
20160046619 

Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities


Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..

02/18/16
20160046602 

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

02/18/16
20160045503 

Formulations containing reversible covalent compounds


Oral pharmaceutical formulations comprising reversible covalent compounds having a michael acceptor moiety, a process of their production and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.. .
Principia Biopharma Inc.


02/11/16
20160039905 

B7-h4 fusion proteins and methods of use thereof


Fusion proteins containing b7-ii4 polypeptides are disclosed. The b7-h4 fusion proteins can include full-length b7-h4 polypeptides, or can contain a fragment of a full-length b7-h4 polypeptide, including some or all of the extracellular domain of the b7-h4 polypeptide.
Amplimmune, Inc.


02/11/16
20160039807 

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)


Wherein cy, l1, g, and r1 are as described herein. The present invention relates to novel compounds according to formula (i) that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g.

02/11/16
20160039784 

Pyrazole derivative


Provided are a compound expressed by formula (i) or a pharmacologically permissible salt thereof, as well as a drug or drug composition that contains this compound as an active ingredient, having a xanthine oxidase inhibiting effect that is very useful for treating or preventing diseases that are contributed to by xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stones, hypertension, dyslipidemia, diabetes, cardiovascular disease such as heart failure and arterial sclerosis, renal disease such as diabetic near opacity and the like, respiratory disease such as chronic obstructive pulmonary disease and the like, autoimmune diseases such as inflammatory bowel disease, and the like. [in the formula, a, x, y, z, r, and r1 have the meaning set forth in claim 1]..
Teijin Pharma Limited


02/11/16
20160038496 

Novel formulations of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc


02/04/16
20160033528 

Methods for selecting peptides that bind to disease specific antibodies, disease specific peptides and uses thereof


Provided herein is a method for selecting and expanding polypeptide epitopes against disease-specific antibodies present in blood across a wide variety of antibody-mediated infectious and autoimmune diseases. In particular, high-throughput selection methods are provided for selecting and expanding disease-relevant polypeptide epitopes against disease-specific antibodies present in a sample from a subject using polypeptide epitope libraries.
The Regents Of The University Of California


02/04/16
20160031934 

Dipeptide and tripeptide epoxy ketone protease inhibitors


Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of formula (x): and pharmaceutically acceptable salts and compositions including the same.
Onyx Therapeutics, Inc.


02/04/16
20160031891 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are amido compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

02/04/16
20160030439 

Methods for the treatment of autoimmune diseases


The present invention provides a method for inducing cd8+foxp3+ regulatory t cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates t-cell receptor (tcr) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject.
Ucl Business Plc


01/28/16
20160024508 

Method for identifying biologically active oligonucleotides capable of modulating the immune system


The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer..
Index Pharmaceuticals Ab


01/28/16
20160024220 

Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis


The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-cd6 monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


01/28/16
20160024219 

Anti-cd52 antibodies


Anti-human cd52 antibodies and antigen-binding fragments thereof are provided. Also provided are isolated nucleic acids, recombinant vectors and host cells for making the antibodies and fragments.
Genzyme Corporation


01/28/16
20160024215 

Llt-1 antibodies with new functional properties


The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (llt1), to polynucleotides encoding such antibodies, and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which llt1- and cd161-expressing cells play a role in disease pathogenesis..
Centre National De La Recherche Scientifique


01/28/16
20160024183 

Synthetic peptides for the treatment of autoimmune diseases


The present invention provides synthetic peptides, including peptides comprising a plurality of epitopes, each epitope being derived from a different protein, and peptides comprising a plurality of citrullinated residues. The present invention also related to use of said peptides for the treatment of autoimmune diseases and disorder..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


01/28/16
20160022788 

Compositions and methods for treating autoimmune diseases


The present invention provides compositions comprising immunologically effective amounts of one or more autoimmune disease associated antigens or antigenic fragments or derivatives thereof and one or more th2 promoting adjuvants. The compositions may optionally comprise one or more th2 promoting tlr2 ligands.
Albany Medical College


01/28/16
20160022767 

Protein particles comprising disulfide crosslinkers and uses


This disclosure relates to particles comprising recombinant proteins, pharmaceutical composition comprising the particles, and therapeutic uses related thereto. In certain embodiments, the particles are made by the process of producing recombinant proteins and conjugating the recombinant proteins to form nanoparticles with a linking reagent comprising disulfide bonds.
Emory University


01/28/16
20160022759 

Methods for increasing the selective efficacy of gene therapy using car peptide and heparan-sulfate mediated macropinocytosis


Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, pah, inflammation, diabetes, crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome.
Vascular Biosciences


01/21/16
20160017024 

Fam150a, fam150b, and fam150 antagonists and uses thereof


Methods of identifying and using fam150a agents, fam150b agents, and fam150 antagonists are provided. Methods of identifying and using ltk agonists (including ltk agonist antibodies, fam150a agents, and fam150b agents) and fam150 antagonists are provided.
Five Prime Therapeutics, Inc.


01/21/16
20160016946 

Methods, compounds, and compositions for the treatment of angiotensin-related diseases


Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.. .
University Of Southern California


01/21/16
20160016904 

Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof


The present invention relates to processes and intermediates useful in the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid of formula (i) and salts thereof, an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development and atherosclerosis).. .
Arena Pharmaceuticals, Inc.


01/21/16
20160015751 

Method for enhancing a function of a t cell


Disclosed is a method for enhancing the function of a t cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (pd-l1) and/or programmed death-1 ligand 2 (pd-l2) in the t cell. Also disclosed is a function-enhanced t cell which is produced by the function enhancement method.
Takara Bio Inc.


01/21/16
20160015729 

Glycan-based drugs, therapies and biomarkers


The present disclosure discloses simple and efficient glycan- or carbohydrate-based processes or methods for the rapid identification of biological markers and therapeutic targets especially glycan-related targets of infectious diseases, cancers, autoimmune diseases, allergies, inflammation, toxicity, obesity and/or other disorders of humans, animals, plants and other organisms. Therefore, novel methods and products for the diagnosis, prevention, and treatment of such diseases obtainable based on these therapeutic targets can be developed..

01/14/16
20160008608 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

01/14/16
20160008440 

Use of cd83 in combination therapies


The present invention relates to improved methods of suppressing and/or preventing an undesired immune response comprising the use of cd83. In some embodiments, cd83 is coadministered to a subject with at least one other immunosuppressive compound.
Argos Therapeutics, Inc.


01/14/16
20160008397 

Immunomodulation by controlling expression levels of micrornas in dendritic cells


Compositions and methods of modulating an immune response by controlling expression levels of micrornas in dendritic cells are disclosed. In particular, the invention relates to modified dendritic cells and methods of using such dendritic cells in cellular therapy for treating various immune conditions and diseases, including transplant rejection, inflammatory disorders, autoimmune diseases, allergies, infectious diseases, immunodeficiency, and cancer..
The Board Of Trustees Of The Leland Stanford Junior University


01/07/16
20160002241 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Llc.


01/07/16
20160002225 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that inhibit bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.

01/07/16
20160002187 

Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
Abbvie Inc.


01/07/16
20160000877 

Compositions and methods for modulating gamma-c-cytokine activity


The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc


01/07/16
20160000867 

Compositions and methods for modulating the immune system


A novel class of embryo derived peptides are described (preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a th2 type cytokine bias, in addition pif enhance endometrial receptivity by increasing adhesion molecules expression. Pif biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages.
Bioincept, Llc


01/07/16
20160000835 

Human uterine cervical stem cell population and uses thereof


The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment..
Fundacion Para La Investigacion Con Celulas Madre Uterinas


12/31/15
20150377879 

Peptoids that bind specific antigens


Combinatorial libraries were generated providing a vast number of diverse peptoid ligands. From these libraries, ligands were identified which specifically bind molecules associated with autoimmune diseases, such as antibodies specific to aquaporin-4 (aqp4), binding of which to aqp4 causes the autoimmune disease, neuoromyelitis optica.
The Scripps Research Institute


12/31/15
20150376294 

Anti-pad2 antibodies and treatment of autoimmune diseases


The present invention relates to anti-peptidylarginine deiminase 2 (pad2) antibodies and anti-pad2 antibodies for use in the treatment of autoimmune diseases characterized by extracellular citrullination, such as rheumatoid arthritis (ra). The invention further relates to a method for treatment of an autoimmune disease characterized by extracellular citrullination comprising the administration of a suitable amount of an anti-pad2 antibody to a subject..
Rigshospitalet


12/31/15
20150376285 

Antibody molecule for human gm-csf receptor alpha


Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (gm-csfrα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g.
Zenyth Operations Pty. Ltd.


12/31/15
20150376174 

Azole benzene derivative


The present invention provides: a compound represented by formula (i) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.. .
Teijin Pharma Limited


12/31/15
20150376173 

Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent


The present invention relates to novel compounds of formula 1 as sphingosine-1-phosphate receptor agonists which can be effectively used for the treatment of autoimmune diseases, a method for preparing the same, and a pharmaceutical composition comprising the same as an active component. The compounds according to the present invention are effective on extensive autoimmune diseases and chronic inflammatory diseases including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulation disorders..
Lg Life Sciences Ltd.


12/31/15
20150374855 

Oral contrast medium for the diagnostic investigation of the gastrointestinal tract by means of mpi


The invention relates to a pharmaceutically acceptable colloidal suspension, which comprises a microcapsule, which is enclosed by a container (“double container”), wherein the microcapsules comprise magnetic particles in a colloidal solution. The invention further relates to the use of said pharmaceutically acceptable colloidal suspension as an oral contrast medium for the diagnostic investigation of the gastrointestinal tract and the use of the contrast medium to diagnose proliferative diseases, inflammatory and autoimmune diseases, infectious diseases and hormonal and hereditary diseases in the gastrointestinal tract..
Topass Gmbh


12/24/15
20150368611 

Induced regulatory t cell and use thereof


The present invention relates to a transduced t cell precursor prepared by introducing a gene construct comprising a polynucleotide encoding c/ebp (ccaat/enhancer binding protein) to a t cell precursor and overexpressing the c/ebp thereby, wherein the transduced t cell precursor is capable of differentiating into a regulatory t cell and an induced regulatory t cell differentiated therefrom. The transduced t cell precursor and the induced regulatory t cell may be useful for preventing and treating autoimmune diseases, inflammatory diseases and graft rejections caused by the malfunction of immune response..
Seoul National University R&db Foundation


12/24/15
20150368261 

Conjugates and small molecules which interact with the cd16a receptor


The invention is related to medicine, in particular, to oncology and immunology. The novel compounds of the general formula 1 or 2, exhibiting affinity for cd16a receptor have been proposed.
Alla Chem, Llc


12/17/15
20150361039 

Sulfonamide compounds and their use in the modulation retinoid-related orphan receptor


The present invention is directed to novel retinoid-related orphan receptor gamma (rorγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by rorγ.. .
Glaxo Group Limited


12/10/15
20150353514 

Amphiphilic derivatives of triazamacrocyclic compounds, products and compositions including same, and synthesis methods and uses thereof


The invention relates to amphiphilic derivatives of a triazamacrocyclic compound, as well as to said derivatives as active molecule transporters. The invention also relates to a nanodrug including at least one amphiphilic derivative of a triazamacrocyclic compound and at least one active molecule of a protein such as an antibody, in particular for the treatment of autoimmune diseases or for the treatment of cancer..
Biocellchallenge


12/10/15
20150352219 

Conjugate compounds


The invention relates to sphingoglycolipid analogues and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.. .
Callaghan Innovation Research Limited


12/10/15
20150352109 

Kinase inhibitor and treatment of related diseases


Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases..
Beijing Reciprocapharmaceuticals Co. Ltd.


11/26/15
20150337041 

Methods and compositions for treating autoimmune diseases or conditions


The present invention relates to methods of treating immune disorders, particularly autoimmune and inflammatory disorders such as rheumatoid arthritis, and methods of producing antibodies for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies that specifically bind to nkg2d receptors present on the surface of cells underlying the disorders..
Fred Hutchinson Cancer Research Center


11/19/15
20150330968 

Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions


The present invention relates to methods and assays for identifying agents capable of modulating gpr84 activity in cells, in particular agents that inhibit gpr84-agonist stimulated chemotaxis. Inhibition of gpr84-agonist stimulated chemotaxis is useful in the prevention and/or treatment of inflammatory conditions.
Galapagos Nv


11/19/15
20150329864 

Design of oligonucleotide analogs as therapeutic agents


It is believed that the compounds and compositions as described herein have therapeutic utility against a variety of diseases, including viral diseases, autoimmune diseases (such as, allergy, asthma, and inflammatory disorders) and cancer.. .

11/19/15
20150329637 

Depletion of il23r expressing cells in the treatment of various diseases


The present invention relates, for example, to depletion of il23r expressing cells in the treatment of disease and, in an embodiment thereof, to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in, for example, treating inflammatory and/or autoimmune diseases and/or cancer.. .
Numab Ag


11/19/15
20150329541 

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-2 protein.. .
The Walter And Eliza Hall Institute Of Medical Research


11/05/15
20150315196 

Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases


Or a pharmaceutically acceptable salt or solvate thereof.. .

11/05/15
20150315191 

4-position substituted pyrazolopyrimidine derivative, and use thereof in drug preparation


The invention provides a new pyrazolopyrimidine derivative and a simple, efficient and low-cost preparation method thereof. The pyrazolopyrimidine derivative of the invention has good inhibitory activity for multiple kinases, has inhibitory action on multiple solid tumors, leukemia and autoimmune diseases, provides a new effective choice for preparation of kinase inhibitors, medicines for autoimmune diseases, angiogenesis inhibitors and antitumor drugs, and has good application prospect..

11/05/15
20150315189 

18f-labelled folates


The present invention is directed towards a new method of synthesis of 18f-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with 18[f]fluoride, as well as 18f-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.. .
Merck & Cie


11/05/15
20150315128 

Bicyclic compounds


And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

11/05/15
20150313899 

Compounds and treating autoimmune diseases


Wherein x and y independently are o or nr1; each r1 is independently h or c1-c6 alkyl; ring a is aryl; each r2 independently is h, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two r2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; r3 and r4 independently are h or c1-c6 alkyl; and r5 is halo, cyano, or c1-c6 alkyl.. .

10/29/15
20150307520 

Novel heteroaryl and heterocycle compounds, compositions and methods thereof


Disclosed are novel heteroaryl and heterocycle compounds of formula i-1, i-2 or i-3 and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of pi3k and for treating inflammatory and autoimmune diseases and cancer.. .
Hutchison Medipharma Limited


10/29/15
20150306103 

Inhibitors of bruton's tyrosine kinase


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics, Inc.


10/22/15
20150301042 

Methods of using chimeric receptors to identify autoimmune disease


The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of graves' disease.
Diagnotic Hybrids, Inc.


10/22/15
20150299197 

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed herein are compounds that inhibit the activity of anti-apoptotic bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.. .
Abbvie Inc.


10/22/15
20150299185 

Novel imidazopyridine derivatives as a tyrosine kinase inhibitor


Provided is a novel imidazopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.. .
Hanmi Pharm. Co., Ltd.


10/22/15
20150299103 

Prodrugs of monomethyl fumarate (mmf)


The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to novel prodrugs of monomethyl fumarate (mmf) suitable as a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis..
Ratiopharm Gmbh


10/22/15
20150297640 

Method of controlling administration of cancer antigen


The present invention is directed to mammalian bi-specific t cells and methods for using these bi-specific t cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific t cells that express a viral antigen t cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting t-cells which express viral antigen.
City Of Hope


10/15/15
20150291554 

Bruton's tyrosine kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Methods for the preparation of the compounds are disclosed.

10/15/15
20150291509 

Novel biphenyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as active ingredient


The present invention relates to a novel biphenyl derivative or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising the same as an active ingredient, and methods for treating inflammatory disease or autoimmune diseases with the pharmaceutical composition. Novel biphenyl derivatives according to the present invention promote the phagocytosis of macrophages and inhibit the chemotaxis to exhibit excellent inflammation terminating and anti-inflammatory effects and thus can be effectively used as therapeutic agents for inflammatory diseases or autoimmune diseases..

10/15/15
20150290317 

Combination of anti-cd20 antibody and pi3 kinase selective inhibitor


Highly effective combinations of a compound of formula a (a pi3kδ selective inhibitor) and anti-cd20 antibodies are provided herein for the treatment and amelioration of pi3kδ and/or cd20 mediated diseases and disorders. In particular, the combination can be used to treat cancers and autoimmune diseases.

10/15/15
20150290284 

Ideotypically modulated pharmacoeffectors for selective cell treatment


In a method embodiment, a method includes introducing a plurality of ideotypically modulated pharmacoeffectors (imp) into a population of cells. Each imp may include a detection domain and an activation domain.

10/08/15
20150284467 

Antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases


The invention relates to antibodies or antibody fragments that bind cd269 (bcma), thereby disrupting the interaction between cd269 and its native ligands (baff and april), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.. .

10/08/15
20150284459 

Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways


Described herein are novel compositions comprising il-27 or nfil-3 modulators (i.e., inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..

10/08/15
20150284410 

Rna polymerase i inhibitors and uses thereof


Provided are novel compounds which are capable of inhibiting an activity of rna polymerase i, and uses thereof in treating diseases or disorders modulated by rna polymerase i, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.. .

10/08/15
20150284399 

Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof


The present invention relates to salts, processes, and process intermediates useful in the preparation of (r)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-1-yl)acetic acid of formula (ia), salts, and crystalline forms thereof. The compound (r)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1h-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an s1p1 receptor modulator that is useful in the treatment of s1p1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis)..

10/08/15
20150283127 

Saquinavir-no for immunomodulation


The nitric ester of saquinavir, or its non-toxic salts, solvates or crystalline/polymorphic forms, i useful in the treatment of autoimmune diseases, particularly in disease mediated by pro-inflammatory cytokines. Examples of diseases which may be treated include idiopathic addison's disease, autoimmune hepatitis, biliary cirrhosis, primary sclerosing cholangitis, guillain barré syndrome, hashimoto's thyroiditis, psoriasis, rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematous, type 1 diabetes mellitus and uveitis of ischemia-reperfusion, graft versus host diseases, graft rejection, endo and exo-toxemia and gouty arthritis..

10/01/15
20150275175 

Therapeutic apoptotic cell preparations, producing same and uses thereof


The present application provides pharmaceutical compositions comprising a population of mononuclear-enriched cells in an early-apoptotic state, methods for the production of said compositions and uses thereof in the treatment of diseases characterized by pathological immune responses. The pharmaceutical compositions may be used in treatment of conditions such as, but not limited to, graft versus host disease (gvhd) and autoimmune diseases including but not limited to inflammatory bowel disease, gout and arthritis..
Enlivex Therapeutics Ltd.




Autoimmune Diseases topics: Immune Diseases, Autoimmune Disease, Autoimmune Diseases, Immune Disease, Autoimmune, Rheumatoid Arthritis, Antibodies, Proliferative, Nucleotide, Antagonist, Infectious Diseases, Inflammatory Disease, Infectious Disease, Infectious, Multiple Sclerosis

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.9898

5554

469273 - 0 - 101